Cancer Research Center of Lyon (CRCL), Lyon 69008, France; INSERM U1052, CNRS UMR-5286, Lyon 69008, France; University of Lyon, Université Claude-Bernard (UCBL), 69008 Lyon, France.
Institute of Virology, Technische Universität München/Helmholtz Zentrum München, Trogerstrasse 30, 81675 Munich, Germany; German Center for Infection Research (DZIF), Munich Site, Germany.
J Hepatol. 2016 Apr;64(1 Suppl):S41-S48. doi: 10.1016/j.jhep.2016.02.009.
HBV deposits a covalently closed circular DNA form, called cccDNA, in the nucleus of infected cells. As the central transcription template, the cccDNA minichromosome is a key intermediate in the HBV life cycle. Its location in the nucleus makes cccDNA a difficult target for antivirals and immune response, and therefore it is responsible for chronicity of HBV infection. While little is known about the mechanisms involved in cccDNA formation, current research is accumulating data on the mechanisms regulating transcription from cccDNA, and the first potential targeting approaches have been reported. This review will summarize our knowledge about cccDNA biology and the latest advances in cccDNA targeting strategies in order to finally achieve an HBV cure.
HBV 在受感染细胞的细胞核中沉积一种称为 cccDNA 的共价闭合环状 DNA 形式。cccDNA 微染色体作为中央转录模板,是 HBV 生命周期中的关键中间产物。cccDNA 位于细胞核内,这使其成为抗病毒和免疫反应的难以攻克的靶点,因此它是导致 HBV 感染慢性化的原因。尽管人们对 cccDNA 形成的机制知之甚少,但目前的研究正在积累有关调节 cccDNA 转录的机制的数据,并且已经报道了第一批潜在的靶向方法。这篇综述将总结我们对 cccDNA 生物学的认识,以及针对 cccDNA 的靶向策略的最新进展,以期最终实现 HBV 的治愈。